{
  "pmcid": "10883654",
  "sha256": "3ca93c108054c43d89eb1f48b67b1f7806392b48b41bf971364ac61839b33aae",
  "timestamp_utc": "2025-11-09T21:58:04.131721+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.29575675675676,
    "reading_ease": 19.509040540540553,
    "word_count": 222
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Neoadjuvant GAP Therapy in Resectable High-Risk Intrahepatic Cholangiocarcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A multi-institutional, single-arm, phase II trial was conducted."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility included tumor size >5 cm, multiple tumors, major vascular invasion, or lymph node involvement."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients received preoperative GAP (gemcitabine 800 mg/m², cisplatin 25 mg/m², nab-paclitaxel 100 mg/m² on days 1 and 8 of a 21-day cycle) for 4 cycles before curative-intent resection."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the feasibility of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel (GAP) in resectable, high-risk IHCC."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary endpoint was completion of chemotherapy and surgery."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Thirty patients were enrolled."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Twenty-two patients (73%, 90% CI 57–86; p=0.008) completed chemotherapy and surgery."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Disease control rate was 90% (progressive disease: 10%, partial response: 23%, stable disease: 67%)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Ten patients (33%) experienced grade ≥3 adverse events, mainly neutropenia and diarrhea; 50% required dose reduction."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}